Pralatrexate for refractory mycosis fungoides in two Japanese patients

Pralatrexate has been approved for the treatment of relapsed/refractory peripheral T cell lymphomas. Studies in the U.S. also support the clinical efficacy of pralatrexate to treat advanced‐stage cutaneous T‐cell lymphomas, but outcomes in Japanese patients have not yet been reported. We herein desc...

Descripción completa

Detalles Bibliográficos
Autores principales: Teraishi, Mika, Oguro, Tokuko, Kusume, Ema, Kobashi, Haruka, Sano, Hozumi, Fujioka, Ai, Yamamoto, Mayuko, Nakajima, Hideki, Sano, Shigetoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Concise Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248132/
https://www.ncbi.nlm.nih.gov/pubmed/33454985
http://dx.doi.org/10.1111/1346-8138.15761
Descripción
Sumario:Pralatrexate has been approved for the treatment of relapsed/refractory peripheral T cell lymphomas. Studies in the U.S. also support the clinical efficacy of pralatrexate to treat advanced‐stage cutaneous T‐cell lymphomas, but outcomes in Japanese patients have not yet been reported. We herein describe two Japanese patients with heavily‐pretreated relapsed/refractory mycosis fungoides that were successfully controlled by pralatrexate.

Ejemplares similares